Dry Eye News and Research

RSS

Dry eye is one of the most common complaints seen by eye doctors, accounting for nearly one fourth of all office visits. Caused by insufficient tear production or excessive tear evaporation, dry eye can be a mild, episodic feeling of discomfort associated with certain circumstances, such as exposure to dry, hot or windy environments; however, it can also be a chronic medical condition that, if left untreated, may lead to increased risk of infection or visual impairment.

Dry eye strikes most often in spring

New ophthalmology research from the University of Miami shows that dry eye - the little understood culprit behind red, watery, gritty feeling eyes - strikes most often in spring, just as airborne allergens are surging.

24 Apr 2015

Mitotech reports positive results from SkQ1 Phase II trial in patients with moderate to severe dry eye syndrome

Mitotech S.A, a Luxembourg-based clinical-stage biotechnology company developing novel antioxidant molecules targeting mitochondria, today announced that it has achieved significant positive results in its U.S. Phase II clinical trial of SkQ1 compound in patients with moderate to severe dry eye syndrome.

24 Apr 2015

Mitotech reports positive results from SkQ1 Phase II trial in patients with moderate to severe dry eye syndrome

24 Apr 2015

RegeneRx joint venture retains Ora to carry out RGN-259/GBT201 clinical trials in U.S.

RegeneRx Biopharmaceuticals, Inc. today announced its U.S. joint venture with G-treeBNT (ReGenTree LLC) has retained Ora, Inc. to conduct a phase 3 clinical trial for the orphan disorder, neurotrophic keratopathy (NK), and a 2b/3 dose-response, confirmatory trial for dry eye syndrome (DES) in the U.S. Both trials will be testing ReGenTree's preservative-free eye drops, RGN-259/GBT201, this year.

16 Apr 2015

BioLight Life Sciences announces first IOPtiMate™ system sale in Hungary

14 Apr 2015

Detecting bladder cancer from urine: an interview with Suzana Nahum-Zilberberg, CEO, BioLight

Bladder cancer is the seventh leading cancer affecting men worldwide and in the United States, it is the fourth leading cancer. Each year, about 350,000 cases are being detected worldwide, and the disease claims 165,000 lives every year.

31 Mar 2015

Loyola ophthalmologist recommends specific foods and supplements for healthy vision

You may remember your mother telling you to eat your carrots; they are good for your eyes. Well, she was right. "Carrots are actually just one of the many foods, and supplements that contribute to good eye health," says James McDonnell, MD, pediatric ophthalmologist, Loyola University Health System. "In some cases, eyesight can actually be improved depending on what you eat."

24 Mar 2015

G-treeBNT to receive $7.28 million to expand international development of RGN-259/GBT-201

RegeneRx Biopharmaceuticals, Inc. has been notified that its joint venture partner and licensee, G-treeBNT Co. Ltd., will receive $7.28 million USD to expand international development of its product candidate, RGN-259 (designated GBT-201).

9 Mar 2015

Rigel Pharmaceuticals reports net loss of $22.3 million for fourth quarter 2014

Rigel Pharmaceuticals, Inc. today reported financial results for the fourth quarter and year ended December 31, 2014. For the fourth quarter of 2014, Rigel reported a net loss of $22.3 million, or $0.25 per share, compared to a net loss of $16.9 million, or $0.19 per share, in the fourth quarter of 2013.

3 Mar 2015

Rigel, Bristol-Myers Squibb partner to develop, commercialize TGF beta receptor kinase inhibitors

Rigel Pharmaceuticals, Inc. and Bristol-Myers Squibb Company today announced that they have entered into a collaboration agreement for the discovery, development and commercialization of cancer immunotherapies based on Rigel's extensive portfolio of small molecule TGF beta receptor kinase inhibitors.

23 Feb 2015

EyePromise® eye vitamins offers education guide to promote awareness on AMD

Due to the aging Baby Boomer population, AMD, or Age-related Macular Degeneration, is expected to double by the year 2020.

4 Feb 2015

Study identifies correlations between BioLight's TeaRx diagnostic parameters and benchmark tests for dry eye syndrome

BioLight Life Sciences Investments Ltd., a firm that invests in, manages and commercializes biomedical innovations in ophthalmology and cancer diagnostics, today announced the completion of a U.S. clinical study, conducted by Ora, Inc. Andover, MA, designed to compare widely used benchmark tests for dry eye with its TeaRx diagnostic parameters that test components of tear film.

3 Feb 2015

Neuroptis reports positive results from ML7 pre-clinical trial for treatment of dry eye syndrome

Neuroptis, a company specialized in the development of drugs to treat eye disorders, today announces positive results from a second animal trial of its preservative-free ML7 eye drops. ML7 is intended for use in the treatment of eye surface diseases, particularly dry eye syndrome.

22 Jan 2015

G-treeBNT files IND with MFDS for Phase IIB/III clinical trial of RGN-259 for dry eye syndrome

RegeneRx Biopharmaceuticals, Inc. announced that its strategic partner, G-treeBNT Co. Ltd., has filed an IND with the Korean Ministry of Food and Drug Safety for a Phase IIB/III clinical trial with RGN-259 (designated GBT-201 in Korea and the licensed Pan Asia territory) for the treatment of patients with dry eye syndrome.

29 Dec 2014

VEGF-B can regenerate damaged peripheral nerves without causing growth of new blood vessels

Researchers at the University of Illinois at Chicago College of Medicine have found that a growth factor can regenerate damaged peripheral nerves without causing the growth of new blood vessels -- making it a unique candidate to treat nerve damage in areas of the body where the proliferation of blood vessels would be a drawback.

18 Nov 2014

Rigel Pharmaceuticals reports net loss of $20.9 million for third quarter of 2014

Rigel Pharmaceuticals, Inc. today reported financial results for the third quarter and nine months ended September 30, 2014.

4 Nov 2014

RegeneRx to begin RGN-259 Phase 3 trials for treatment of neurotrophic keratopathy

RegeneRx Biopharmaceuticals, Inc. ("the Company" or "RegeneRx") today announced that it met with the FDA in September and as a result of the meeting may begin Phase 3 to evaluate RGN-259 preservative-free eye drops for the treatment of patients with neurotrophic keratopathy (NK), an orphan disease of the cornea.

20 Oct 2014

Researchers develop nanoparticle eye drops to combat dry eye syndrome

For the millions of sufferers of dry eye syndrome, their only recourse to easing the painful condition is to use drug-laced eye drops three times a day.

9 Oct 2014

RPS Diagnostics receives CE mark for FebriDx test

RPS Diagnostics, Inc. today announced CE mark of its FebriDx test, clearing the way for sales in the European Union and all countries recognizing the CE mark.

9 Oct 2014

Center Director of Omni Eye Surgery describes promising option for managing lid disease

Omni Eye Services, a leading provider of ophthalmologic services at five locations in New York and New Jersey, today announced that Dr. Katherine M Mastrota, Center Director of Omni Eye Surgery in New York City, has written a treatment update for Contact Lenses Today describing a promising "new option for managing lid disease."

9 Sep 2014

Dry Eye News and Research

Further Reading

Dry eye strikes most often in spring

Mitotech reports positive results from SkQ1 Phase II trial in patients with moderate to severe dry eye syndrome

Mitotech reports positive results from SkQ1 Phase II trial in patients with moderate to severe dry eye syndrome

RegeneRx joint venture retains Ora to carry out RGN-259/GBT201 clinical trials in U.S.

BioLight Life Sciences announces first IOPtiMate™ system sale in Hungary

Detecting bladder cancer from urine: an interview with Suzana Nahum-Zilberberg, CEO, BioLight

Loyola ophthalmologist recommends specific foods and supplements for healthy vision

G-treeBNT to receive $7.28 million to expand international development of RGN-259/GBT-201

Rigel Pharmaceuticals reports net loss of $22.3 million for fourth quarter 2014

Rigel, Bristol-Myers Squibb partner to develop, commercialize TGF beta receptor kinase inhibitors

EyePromise® eye vitamins offers education guide to promote awareness on AMD

Study identifies correlations between BioLight's TeaRx diagnostic parameters and benchmark tests for dry eye syndrome

Neuroptis reports positive results from ML7 pre-clinical trial for treatment of dry eye syndrome

G-treeBNT files IND with MFDS for Phase IIB/III clinical trial of RGN-259 for dry eye syndrome

VEGF-B can regenerate damaged peripheral nerves without causing growth of new blood vessels

Rigel Pharmaceuticals reports net loss of $20.9 million for third quarter of 2014

RegeneRx to begin RGN-259 Phase 3 trials for treatment of neurotrophic keratopathy

Researchers develop nanoparticle eye drops to combat dry eye syndrome

RPS Diagnostics receives CE mark for FebriDx test

Center Director of Omni Eye Surgery describes promising option for managing lid disease

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News